First human data for a 'rejuvenate the eye' therapy arrives tomorrow

Tomorrow afternoon in New Orleans, a biotech company will show the first human data for a therapy designed to do something medicine has never done: rewind the age of cells inside a living person's eye. Life Biosciences announced it will present interim results from the Phase 1 trial of ER-100 — its epigenetic-reprogramming candidate for optic neuropathies — at Eyecelerator @ AAO 2026 on October 8.

What ER-100 is — and what's being presented

ER-100 is the first clinical candidate from Life Bio's Epigenetic Restoration platform: controlled expression of three transcription factors — OCT4, SOX2, and KLF4, the OSK trio — that reset the epigenetic code toward more youthful patterns of gene expression. The ongoing first-in-human trial is testing safety and tolerability in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), with additional endpoints measuring visual function.

Chief Scientific Officer Sharon Rosenzweig-Lipson will present the data at 2:10 pm CT on October 8 in the Glaucoma Digital session. As she framed it, the goal isn't just slowing vision loss but potentially reversing the underlying damage to retinal ganglion cells — for which patients currently have no therapeutic options.

The mitochondria connection — and what to watch

Why does this belong on a mitochondria site? Because the optic nerve is one of the body's most mitochondrial stories. Retinal ganglion cells are enormously energy-hungry neurons, and mitochondrial failure sits at the center of optic neuropathies — Leber hereditary optic neuropathy, the classic blinding disease, is a mitochondrial DNA disease. And the preclinical foundation of partial reprogramming includes restoration of mitochondrial gene programs and function in aged retinal ganglion cells.

The discipline to hold: this is a Phase 1 safety presentation, not an efficacy readout. What to watch for tomorrow is the safety profile, any early visual-function signal, and how the company frames the path forward. Rejuvenation claims need human data; tomorrow we get the first look at whether the human chapter has begun.

Where the evidence stands

• Established: The ER-100 Phase 1 trial is underway in optic neuropathies (open-angle glaucoma, NAION), measuring safety, tolerability, and visual function; interim data present October 8, 2026.
• Preliminary: Partial OSK reprogramming restored aged retinal ganglion cell function — including mitochondrial gene programs — in preclinical models.
• Absent: Any human efficacy or safety data for ER-100; whether epigenetic reprogramming translates to vision gains in people.